Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

The Patient's Perspective of the Intensive Care Unit Diary in the Cardiac Intensive Care Unit.

Levine SA, Reilly KM, Nedder MM, Avery KR.

Crit Care Nurse. 2018 Aug;38(4):28-36. doi: 10.4037/ccn2018970.

PMID:
30068718
2.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

3.

Developing Professional Practice and Ethics Engagement: A Leadership Model.

Reilly KM, Jurchak M.

Nurs Adm Q. 2017 Oct/Dec;41(4):376-383. doi: 10.1097/NAQ.0000000000000251.

PMID:
28859007
4.

Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.

Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC.

Sarcoma. 2017;2017:7429697. doi: 10.1155/2017/7429697. Epub 2017 May 16. Review.

5.

Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamimov A, Stewart DR, Viskochil D, Widemann B, Perry A.

Hum Pathol. 2017 Sep;67:1-10. doi: 10.1016/j.humpath.2017.05.010. Epub 2017 May 24. Review.

6.

Blogging as an Innovative Method of Peer-to-Peer Educational Sharing.

Nedder MM, Levine SA, Galligan C, Avery KR, Eagan-Bengston E, Reilly KM.

Crit Care Nurse. 2017 Feb;37(1):e1-e9. doi: 10.4037/ccn2017642.

7.

The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Karmakar S, Reilly KM.

CNS Oncol. 2017 Jan;6(1):45-60. doi: 10.2217/cns-2016-0024. Epub 2016 Dec 21. Review.

8.

The Effects of Genetic Background of Mouse Models of Cancer: Friend or Foe?

Reilly KM.

Cold Spring Harb Protoc. 2016 Mar 1;2016(3):pdb.top076273. doi: 10.1101/pdb.top076273.

PMID:
26933251
9.

Using the Collaborative Cross to Study the Role of Genetic Diversity in Cancer-Related Phenotypes.

Reilly KM.

Cold Spring Harb Protoc. 2016 Mar 1;2016(3):pdb.prot079178. doi: 10.1101/pdb.prot079178.

PMID:
26933242
10.

Controlling Genetic Background in Crosses of Mouse Models of Cancer.

Reilly KM.

Cold Spring Harb Protoc. 2016 Mar 1;2016(3):pdb.prot079160. doi: 10.1101/pdb.prot079160.

PMID:
26933241
11.

Deguelins, Natural Product Modulators of NF1-Defective Astrocytoma Cell Growth Identified by High-Throughput Screening of Partially Purified Natural Product Extracts.

Henrich CJ, Cartner LK, Wilson JA, Fuller RW, Rizzo AE, Reilly KM, McMahon JB, Gustafson KR.

J Nat Prod. 2015 Nov 25;78(11):2776-81. doi: 10.1021/acs.jnatprod.5b00753. Epub 2015 Oct 15.

PMID:
26467198
12.

Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.

Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage EJ, Walrath J, Reilly KM, Abel HJ, Pekmezci M, Perry A, Ley TJ, Gutmann DH.

Clin Cancer Res. 2015 Sep 15;21(18):4201-11. doi: 10.1158/1078-0432.CCR-14-3049. Epub 2015 Apr 29.

13.

The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Warrington NM, Sun T, Luo J, McKinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, Stevenson DA, Viskochil D, Druley TE, Forys JT, Reilly KM, Fisher MJ, Tabori U, Allen JC, Schiffman JD, Gutmann DH, Rubin JB.

Cancer Res. 2015 Jan 1;75(1):16-21. doi: 10.1158/0008-5472.CAN-14-1891. Epub 2014 Nov 7.

14.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

15.

Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals.

Lockett S, Verma C, Brafman A, Gudla P, Nandy K, Mimaki Y, Fuchs PL, Jaja J, Reilly KM, Beutler J, Turbyville TJ.

Cytometry A. 2014 Jun;85(6):512-21. doi: 10.1002/cyto.a.22442. Epub 2014 Feb 11.

16.

Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.

Devkota KP, Wilson JA, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

Phytochem Lett. 2014 Feb 1;7:42-45.

17.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013. Erratum in: PLoS One. 2014;9(6):e101827.

18.
19.

Process and outcomes of patient-centered medical care with Alaska Native people at Southcentral Foundation.

Driscoll DL, Hiratsuka V, Johnston JM, Norman S, Reilly KM, Shaw J, Smith J, Szafran QN, Dillard D.

Ann Fam Med. 2013 May-Jun;11 Suppl 1:S41-9. doi: 10.1370/afm.1474.

20.

Isobutylhydroxyamides from the pericarp of Nepalese Zanthoxylum armatum inhibit NF1-defective tumor cell line growth.

Devkota KP, Wilson J, Henrich CJ, McMahon JB, Reilly KM, Beutler JA.

J Nat Prod. 2013 Jan 25;76(1):59-63. doi: 10.1021/np300696g. Epub 2012 Dec 26.

21.

Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

Amlin-Van Schaick JC, Kim S, DiFabio C, Lee MH, Broman KW, Reilly KM.

Neuro Oncol. 2012 Feb;14(2):160-74. doi: 10.1093/neuonc/nor206. Epub 2012 Jan 10.

22.

Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Amlin-Van Schaick J, Kim S, Broman KW, Reilly KM.

Mamm Genome. 2012 Apr;23(3-4):277-85. doi: 10.1007/s00335-011-9380-0. Epub 2011 Dec 8.

23.

Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.

Gürsel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC, Reilly KM.

Neuro Oncol. 2011 Jun;13(6):610-21. doi: 10.1093/neuonc/nor035.

24.

Back to the future: proceedings from the 2010 NF Conference.

Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Gareth Evans D, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu Y, Hunter-Schaedle K, Giancotti FG.

Am J Med Genet A. 2011 Feb;155A(2):307-21. doi: 10.1002/ajmg.a.33804. Epub 2010 Dec 22.

25.

Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.

Turbyville TJ, Gürsel DB, Tuskan RG, Walrath JC, Lipschultz CA, Lockett SJ, Wiemer DF, Beutler JA, Reilly KM.

Mol Cancer Ther. 2010 May;9(5):1234-43. doi: 10.1158/1535-7163.MCT-09-0834. Epub 2010 May 4.

26.

Genetically engineered mouse models in cancer research.

Walrath JC, Hawes JJ, Van Dyke T, Reilly KM.

Adv Cancer Res. 2010;106:113-64. doi: 10.1016/S0065-230X(10)06004-5. Review.

27.

Evidence of perturbations of cell cycle and DNA repair pathways as a consequence of human and murine NF1-haploinsufficiency.

Pemov A, Park C, Reilly KM, Stewart DR.

BMC Genomics. 2010 Mar 22;11:194. doi: 10.1186/1471-2164-11-194.

28.

Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis.

Hawes JJ, Reilly KM.

Toxicol Pathol. 2010 Jan;38(1):123-30. doi: 10.1177/0192623309357075.

PMID:
20176786
29.

The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.

Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH.

Cancer Res. 2010 Feb 15;70(4):1356-66. doi: 10.1158/0008-5472.CAN-09-2178. Epub 2010 Feb 2.

30.

Neurofibromatosis and lessons for the war on cancer.

Reilly KM.

EMBO Mol Med. 2009 Jul;1(4):198-200. doi: 10.1002/emmm.200900029.

31.

Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner.

Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quiñones OA, Reilly KM.

Mamm Genome. 2009 Apr;20(4):214-23. doi: 10.1007/s00335-009-9179-4. Epub 2009 Apr 4.

32.
33.

Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk.

Reilly KM.

Brain Pathol. 2009 Jan;19(1):121-31. doi: 10.1111/j.1750-3639.2008.00236.x.

34.

It takes a (dysfunctional) village to raise a tumor.

Reilly KM, Van Dyke T.

Cell. 2008 Oct 31;135(3):408-10. doi: 10.1016/j.cell.2008.10.009.

35.

Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.

Hawes JJ, Nerva JD, Reilly KM.

J Biomol Screen. 2008 Sep;13(8):795-803. doi: 10.1177/1087057108321085. Epub 2008 Jul 29.

36.

Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop.

Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, Gutmann DH.

Cancer Res. 2008 Jul 15;68(14):5508-11. doi: 10.1158/0008-5472.CAN-08-0703. No abstract available.

37.
38.

Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.

Hawes JJ, Tuskan RG, Reilly KM.

Neurogenetics. 2007 Apr;8(2):121-30. Epub 2007 Jan 11.

PMID:
17216419
39.

The report of the APSAC Task Force on Attachment Therapy, Reactive Attachment Disorder, and Attachment Problems.

Lyon L, Reilly KM, Donnis R.

Child Maltreat. 2006 Nov;11(4):375-7; author reply 381-6. No abstract available.

PMID:
17043323
40.

Odds of critical injuries in unrestrained pediatric victims of motor vehicle collision.

Chan L, Reilly KM, Telfer J.

Pediatr Emerg Care. 2006 Sep;22(9):626-9.

PMID:
16983245
41.

A novel in vivo model to study endochondral bone formation; HIF-1alpha activation and BMP expression.

Emans PJ, Spaapen F, Surtel DA, Reilly KM, Cremers A, van Rhijn LW, Bulstra SK, Voncken JW, Kuijer R.

Bone. 2007 Feb;40(2):409-18. Epub 2006 Sep 18.

PMID:
16979964
42.

An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model.

Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, Sun Z, Diehl J, Munroe DJ, Tuskan RG.

Cancer Res. 2006 Jan 1;66(1):62-8.

43.

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H.

J Transl Med. 2004 Nov 24;2(1):40.

44.

The importance of genome architecture in cancer susceptibility: location, location, location.

Reilly KM.

Cell Cycle. 2004 Nov;3(11):1378-82. Epub 2004 Nov 30.

PMID:
15492507
45.

Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T.

Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13008-13. Epub 2004 Aug 19.

46.

Comparative pathology of nerve sheath tumors in mouse models and humans.

Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M.

Cancer Res. 2004 May 15;64(10):3718-24.

47.

Integration of digital imaging into emergency medicine education.

Chan L, Reilly KM.

Acad Emerg Med. 2002 Jan;9(1):93-5. Review.

48.

Genetically engineered mouse models of astrocytoma: GEMs in the rough?

Reilly KM, Jacks T.

Semin Cancer Biol. 2001 Jun;11(3):177-91. Review.

PMID:
11407943
49.

Etanercept in juvenile rheumatoid arthritis.

Johnson CJ, Reilly KM, Murray KM.

Ann Pharmacother. 2001 Apr;35(4):464-71. Review.

PMID:
11302411
50.

Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes.

Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH.

Glia. 2001 Mar 15;33(4):314-23.

PMID:
11246230

Supplemental Content

Loading ...
Support Center